Mailleux P, Przedborski S, Beaumont A, Verslijpe M, Depierreux M, Levivier M, Kitabgi P, Roques B P, Vanderhaeghen J J
Laboratory of Neuropathology and Neuropeptide Research, Faculty of Medicine, Brugmann Hospital, Bruxelles, Belgium.
Peptides. 1990 Nov-Dec;11(6):1245-53. doi: 10.1016/0196-9781(90)90159-3.
The presence of neurotensin receptors and endopeptidase 24.11 (E-24.11) in 16 human meningioma specimens, obtained at surgery, was assessed by measuring the binding of 125I-[tyrosyl3]neurotensin(1-13) (125I-NT) and the inhibitor 3H-N(2RS)-3-hydroxyaminocarbonyl-2-benzyl-1-oxopropyl)glycine (3H-HACBO-Gly), for the receptor and enzyme, respectively. E-24.11 activity was also measured. Autoradiography, on the 16 meningiomas, showed that specific 125I-NT labeling (nonspecific labeling was assessed in the presence of excess NT) was exclusively located in the meningothelial regions. In contrast, specific 3H-HACBO-Gly labeling (nonspecific labeling was assessed in the presence of an excess of the E-24.11 inhibitor thiorphan) was exclusively found in fibroblastic regions. No specific labeling of either ligand was found on collagen or blood vessels. In vitro binding assays were performed on membranes of 10 of the 16 meningiomas. In the 4 meningiomas rich in meningothelial cells, 125I-NT specifically bound to one population of sites with Bmax ranging from 57 to 405 fmol/mg protein and Kd around 0.3 nM. These sites share common properties with the brain NT receptor, since the carboxy terminal acetyl NT(8-13) fragment bound to the same sites but with a higher affinity. The carboxy terminal analogue of NT, neuromedin N, also bound to the same sites with a 10-fold lower affinity and the sites were bradykinin and levocabastine insensitive. In the 4 meningiomas rich in fibroblastic cells, 3H-HACBO-Gly specifically bound to one population of sites with Bmax ranging from 251 to 739 fmol/mg protein and Kd around 2.8 nM.(ABSTRACT TRUNCATED AT 250 WORDS)
通过分别测量125I-[酪氨酰3]神经降压素(1 - 13)(125I-NT)和抑制剂3H-N(2RS)-3-羟基氨基羰基-2-苄基-1-氧代丙基)甘氨酸(3H-HACBO-Gly)与受体和酶的结合,评估了手术获取的16份人类脑膜瘤标本中神经降压素受体和内肽酶24.11(E-24.11)的存在情况。同时也测量了E-24.11活性。对16例脑膜瘤进行放射自显影显示,特异性125I-NT标记(非特异性标记在过量NT存在下评估)仅位于脑膜内皮区域。相反,特异性3H-HACBO-Gly标记(非特异性标记在过量E-24.11抑制剂硫丙拉嗪存在下评估)仅在成纤维细胞区域发现。在胶原或血管上未发现两种配体的特异性标记。对16例脑膜瘤中的10例的膜进行了体外结合试验。在4例富含脑膜内皮细胞的脑膜瘤中,125I-NT特异性结合到一群位点,Bmax范围为57至405 fmol/mg蛋白质,Kd约为0.3 nM。这些位点与脑NT受体具有共同特性,因为羧基末端乙酰化NT(8 - 13)片段以更高亲和力结合到相同位点。NT的羧基末端类似物神经介素N也以低10倍的亲和力结合到相同位点,且这些位点对缓激肽和左卡巴斯汀不敏感。在4例富含成纤维细胞的脑膜瘤中,3H-HACBO-Gly特异性结合到一群位点,Bmax范围为251至739 fmol/mg蛋白质,Kd约为2.8 nM。(摘要截短于250字)